New York-headquartered, Israeli-founded AI biotech company Immunai has expanded its collaboration with AstraZeneca in oncology clinical development, with Immunai eligible to receive up to $37.5 million over 2026 and 2027, the company said in a statement.

The expanded agreement extends and broadens the companies’ multi-year collaboration in oncology through 2027, according to the statement. AstraZeneca will continue using Immunai’s AMICA-OS AI operating system, which combines clinical immunology data at single-cell resolution with advanced AI models of the immune system.

The platform is designed to support oncology drug development by helping generate insights for biomarker discovery, patient stratification, mechanism-of-action analysis, and dose optimization, Immunai said.

The agreement marks the third expansion of the collaboration between Immunai and AstraZeneca. It follows a 2024 agreement to apply Immunai’s platform across AstraZeneca oncology clinical programs and a 2025 agreement expanding the collaboration into inflammatory bowel disease.

“Across AstraZeneca, we are continuously investing in frontier AI models and solutions to inform clinical development decisions and derive novel mechanistically informed biomarkers,” said Jorge Reis-Filho, Chief of AI for Science Innovation at AstraZeneca. “The expansion of this ongoing collaboration is a reflection of our conviction in the transformative potential of AI to improve patient outcomes.”

Noam Solomon, PhD, CEO of Immunai, said AstraZeneca’s decision to deepen the collaboration reflected the value of the platform.

“The fact that AstraZeneca continues to deepen this collaboration is a strong signal for us that the platform is delivering,” Solomon said. “We are focused on generating insights that are mechanistically grounded and clinically relevant, and collaborations like this one are how we get there.”

Immunai uses single-cell genomics and machine learning to study the human immune system and support the development of therapeutics. Its AMICA-OS platform integrates large-scale immune data with AI models to generate insights that the company says can be used in drug development.

The company is headquartered in New York City and has offices in Tel Aviv, Prague, and Zurich. Immunai said it has more than 170 experts and has raised close to $270 million to date.